

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2026

HARVARD BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-33957

(Commission File Number)

04-3306140

(I.R.S. Employer Identification No.)

84 October Hill Road
Holliston, MA 01746

(Address of Principal Executive Offices) (Zip Code)

(508) 893-8999

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value	HBIO	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.Corporate Presentation

The Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. A copy of the Company's current corporate slide presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.**(d) Exhibits.**

EXHIBIT NUMBER	EXHIBIT DESCRIPTION
<u>99.1</u>	<u>Corporate slide presentation of Harvard Bioscience, Inc., dated August 2026.</u>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HARVARD BIOSCIENCE, INC.

Date: August 11, 2026

By: /s/ Mark Frost
Mark Frost
Chief Financial Officer



NASDAQ: HBIO

Harvard Bioscience Investor Overview

August 2026



Forward-Looking Statements & Non-GAAP Financial Information

Forward Looking Statements

This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, gross margins, adjusted EBITDA and EBITDA margin, cash and debt position, growth and the introduction of new products, and the strength of the Company's market position and business model and anticipated macroeconomic conditions. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company's control. Risks and other factors that could cause the Company's actual results to differ materially from those described in its forward-looking statements include those described in the "Risk Factors" section of the Company's most recently filed Annual Report on Form 10-K as well as in the Company's other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company's expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.

Use of Non-GAAP Financial Information

This document contains non-GAAP financial information, including one or more of adjusted operating income (loss), adjusted operating margin, adjusted net income (loss), adjusted EBITDA, adjusted EBITDA margin, diluted adjusted earnings (loss) per share, and net debt. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of our business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income resulting from items that we do not believe are representative of the underlying operations of the business. Items excluded include stock-based compensation, amortization of intangibles related to acquisitions, restructuring charges, other operating expenses, goodwill impairment, interest and other expenses, net, income taxes, and the tax impact of reconciling items. Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors and financial analysts in assessing the Company's operating performance.

Historical non-GAAP financial information included herein is accompanied by a reconciliation to the nearest corresponding GAAP measure, which is included below. In addition, the forward-looking Adjusted gross margin and Adjusted EBITDA guidance for the third quarter of 2026 and full-year 2026 excludes potential charges or gains that may be recorded during the fiscal year, including among other things, restructuring and reorganization expenses, and non-GAAP restructuring related expenses. The Company has not attempted to provide reconciliations of such forward-looking non-GAAP earnings guidance to the comparable GAAP measure, as permitted by Item 10(e)(1)(i)(B) of Regulation S-K, because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be misleading to investors. Such items could have a substantial impact on GAAP measures of the Company's financial performance.

With respect to non-GAAP forward-looking measures, we provide an outlook for adjusted EBITDA margin. Many of the items that we exclude from this forward-looking measure calculation may not be subject to the control of or may not be reliably predicted by management. These items could cause our non-GAAP forward looking measures to vary materially from measures reported under GAAP.

The non-GAAP financial information provided in this document should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies' non-GAAP financial information.

Vision

*“Accelerating drug development
through human-relevant
translational tools”*

Harvard Bioscience By The Numbers

Harvard Bioscience builds tools that power translational research across drug discovery & preclinical development

\$87M

Revenue
FY25

Guiding 3-5% growth in FY26

58%

Adj. Gross Margin*
FY25

Guiding 57-59% in FY26

\$8M

Adj. EBITDA*
FY25

Guiding 6-10% growth in FY26

54%

Recurring Revenue
(path to 60%+)

#1 or #2

in 7 of 10 product
lines

10,000+

Customers



FY25 revenue more than 1.5x company enterprise value*

*Enterprise value as of 3/13/26



* Non-GAAP measure, see Slides 28-31 for reconciliation to GAAP financial measures

Recent Actions

✓ **New Executive Leadership:** Appointed John Duke CEO effective July 2025 & made Mark Frost permanent CFO in March of 2026

✓ **Expanded Board of Directors:** Appointed Rob Gagnon & Seth Benson effective July 2025, Stephen DeNelsky effective September 2025, BroadOak Partner Bill Snider effective December 2025

✓ **Focused Strategic Direction:** Announced focus on Translational Science products in February 2026

✓ **Debt Refinancing:** Extended debt maturity to 2029, reduced annual debt service generating \$3 million in annual cash savings, & enhanced financial flexibility to support long term growth objectives & BroadOak made \$7.5M investment in convertible notes

✓ **Strategic Consolidation:** Streamlining production footprint & improving manufacturing efficiency through phased closure of Holliston, MA plant – expected to deliver approximately \$3 million of adjusted EBITDA improvement in 2027 and \$4 million of improvement beginning in 2028

Debt Refinancing: \$40M Deal Structure

Term Loan	Amount	Interest Rate	Maturity	Amortization	Prepayment Penalty	Exit Fee	Conversions	BroadOak
A	\$10M	Per annum rate: greater of (i) 12.80% (first 2 years), then 12.50%; (ii) or prime rate + 5.25%	December 2029 Maturity may extend one year if adjusted EBITDA milestone is achieved	Commencing December 31, 2027, the Company is required to make quarterly principal amortization payments	Year 1: 3.00% Year 2: 2.00% Year 3: 1.00% Year 4+: 0%	10.00% exit fee on all prepaid or repaid amounts (including at maturity)	Can be converted to ABL providing lower interest rate, more flexibility, and reduction of Exit fee	BroadOak received warrants for 200K shares at \$5.00/share Right to nominate one board member while loans remain outstanding (BroadOak partner Bill Snider nominated)
B	\$22.5M			The Amortization Date may be extended by one year if adjusted EBITDA milestone is achieved	No prepayment premium on Term A Loan prepaid before March 31, 2027	Can be reduced by 50% on Term Loan A if Asset Based Loan (ABL) completed	N/A	
C	\$7.5M			N/A	Term C Loan may not be prepaid, except in the event of a repayment in full of all of the Term Loans or a change of control of the Company, in which case the Lenders may elect whether to convert their Term C Loans into Common Stock or to be repaid in full in cash.	No exit fee on Term C Loan that converts into Common Stock	Converts to common stock at \$10.00/share (Jan 2, 2026 – maturity) Auto-converts if share price exceeds \$15.00 for 30 consecutive trading days	

Reduced annual debt service generating \$3 million in annual cash savings

Project Viking: Strategic Manufacturing Consolidation



RELOCATION DETAILS

- Consolidating Holliston, MA manufacturing site over a 15-month period, with expected completion by the end of 1Q27.
- All U.S. production will be based in Minneapolis, MN.
- Certain products will be consolidated to facilities in Germany, Sweden, and the U.K., to align specific product lines with their designated center of excellence.
- The Company is building surplus inventory to ensure no customer disruption.



Investment Highlights: Strong Foundation Poised for Growth

Market Leadership with Structural Tailwinds	#1 preclinical telemetry franchise for 35+ years, & early organoid leadership
Blue-Chip Customer Base	Selling to diverse, blue-chip customer base on a global scale
Recurring Revenue, High Margins & Positive Cash Flow	Software, consumables, installed base drive visibility & margin expansion on products with high barrier to entry, generating increased cash for the Company
Differentiated New Product Innovation (NPI) Pipeline	MeshMEA™, SoHo™, Incub8™ extend leadership into high-growth adjacencies
New Management & BoD	Refocused management team with deep experience supported by technically deep employee base & refreshed board of directors
Strengthened Balance Sheet & Streamlined Operations	Refinancing & manufacturing consolidation unlock operating leverage

Key Strategic Pillars: The New Harvard Bioscience

Historically known as life sciences tools company, becoming pure play Translational Science Tools company

Lead the Translational Bridge	Scale High-Margin Innovation	Expand Recurring Revenue Mix	Operate with Discipline
Integrate in vivo telemetry with in vitro organoid platforms	Advance differentiated NPI in telemetry, electrophysiology, & organoids	Grow consumables, software, & services attached to installed base	Use preclinical cash flows to fund R&D, margin expansion, & bolt-ons



Positioning Company For Long-Term Growth

An Evolving Translational Science Market

Regulatory, scientific, & economic shift in drug development

- **Regulators usher in new tools:** FDA, EMA, & other global regulators are actively pushing the adoption of New Approach Methodologies (NAMs)
 - NAMs are human relevant technologies geared to reduce failure rates in drug discovery – currently, over 90% of drugs that pass animal trials fail in human trials
- **Scientific tailwinds:** NAMs have demonstrated a technical improvement in modeling biologic outcomes
 - The FDA is encouraging submission of NAMs data, in addition to animal data, for new drug applications, which creates an additional market for our products
- **Innovation continues:** Next-gen organoid & 3D systems rapidly advance

HBIO is uniquely positioned to lead during this transition


- **Decades-long pre-clinical tools leadership:** deep industry relationships with biopharma, CROs, regulators, & research institutions
- **Workflow coverage:** Products span across the translational science space from foundational tools to the latest NAM technologies (MeshMEA™)
- **Installed advantage:** Millions of products sold to thousands of customers around the globe & across the drug development ecosystem

\$10B+
Translational
Tools Market

Global Footprint & Distribution – Built to Scale Efficiently

A global operating platform with embedded growth leverage

- Strong commercial organization with 45 highly technical, deeply knowledgeable direct sales representatives
- Considerable manufacturing flexibility across five facilities adequately covers NA, EMEA, & Asia
- JD Edwards ERP system consolidation (completed in 2024) improved sales & operations planning
- Streamlining production footprint & improving manufacturing efficiency through phased closure of Holliston, MA plant




Blue-Chip Customers Across Multiple Revenue Streams

	ACADEMIC RESEARCH 50% of 2025 Revenue	BIOTECH, PHARMACEUTICAL 28% of 2025 Revenue	CONTRACT RESEARCH ORGANIZATIONS 22% of 2025 Revenue
Who			
What	- Scientific Research labs primarily government & grant funded - Early discovery of new novel drugs & compounds for therapies & vaccines - Advanced cellular testing & gene editing	- Perform early discovery & then transition from discovery through preclinical regulatory & on to production - Leverage discoveries from academics & biotech's - Bridge to bio-production	- Preclinical studies to determine safety & efficacy of new pharmaceuticals - Pharmaceutical companies are outsourcing significant preclinical activities to CROs
Why	Breakthrough technologies & applications drive innovation	Reduced development cycle time drives BioPharma revenue growth	Reduced test cycle-time drives CROs revenue growth

Direct Sales Force Complemented by Key Distributors for Global Reach

CHANNEL REVENUE MIX
2025 REVENUE BY SALES CHANNEL



- Signed Fisher North America agreement in August 2025, which increases customer access
- Working to sign similar agreement with another distributor in 2026, which would expand reach into large pharma

SALES FORCE GEOGRAPHY
2025 SALES REPS BY REGION




- Effective direct sales channel supported by 45 highly technical, deeply knowledgeable direct sales representatives
- Global reach with strategic geographic mix based on sales & distribution footprint

Broad Portfolio Serves as One Stop Shop for Customers

- Leading provider of products across the drug development cycle, spanning research & discovery, bioproduction & preclinical testing
- Diversified offerings that span the gamut of preclinical workflows & applications
- Top-tier market positions across the majority of product lines

Drug Discovery Life Cycle & Where We Fit In




Organoids & MeshMEA™: Powering Shift to Human-Relevant Discovery

FIRST & DIFFERENTIATED



Industry's first platform for long-term functional recording inside living organoids

- Enables continuous neuro & cardiac data over weeks to months



MeshMEA™

FASTER & MORE PREDICTIVE



Earlier safety & efficacy insights versus traditional animal models

- Improves compound selection while reducing development time & cost



MEA2100 Mini System

Incub8™ System

RECURRING & HIGH-MARGIN



Integrated hardware, consumables, & advanced analysis software

- Creates high switching costs & expanding recurring revenue streams



MCS Software Platform

NPI Pipeline Provides High Growth Opportunities

STRENGTHEN THE BASE: MARKET LEADERSHIP & PROFITABLE GROWTH



PRECLINICAL



CMT

- Ponemah™ Enterprise Data Acquisition/Analysis GLP
- Introduced 2nd release of SoHo shared housing implantable telemetry system to extend leadership in wireless telemetry
- Introduced VivaMARS™ high-volume GLP behavioral system
- Well established cellular/molecular/inhalation-respiration technologies for research/discovery
- Recurring revenue streams from consumables, software & services



HIGH-GROWTH PLATFORMS: FROM INVESTMENT TO IMPACT

Bio-Production



CMT

- BTX® electroporation / electrofusion system
- Supports latest applications in cell & gene editing, cell & gene therapy (CGT)
- Introduced BTX & Amino Acid Analysis for bioproduction



In-Vitro Organoid Apps



CMT - ORGANOIDs


- Introduced breakthrough MeshMEA™ organoid platform
- Leverages leadership position in advanced electrophysiology with Incub8™ platform
- Adapts leading MEA technology to emerging organoid applications in neuro & cardiac safety toxicology



Recurring Revenue, Strong Margins & Cash Generation

Recurring Revenue

54% recurring consumables, software & services revenue



46% non-recurring equipment revenue

Note: represents full year 2025 revenue mix

- 54% recurring revenue in 2025
- Clear path to 60% recurring revenue
- Focusing NPI on resources & investments on higher-margin consumables service & software

High Gross Margin

Gross Margin by Quarter



- Improvement driven by cost reductions to date
- Maintaining cost discipline & operational efficiency going forward
- Differentiated & innovative high-margin platforms such as SoHo™ telemetry, & proprietary MeshMEA & Incub8 platforms

Positive Cash Flow

Cash From Operations



- Cash generation driven by operational improvements
- Manufacturing consolidation expected to unlock additional efficiencies
- Additional cash will provide opportunity to invest in innovation

2Q26 Financial Metrics (GAAP except where noted)

\$ Million except
per share data



* Non-GAAP measure, see Slides 28-31 for reconciliation to GAAP financial measures

Outlook

REVENUE

3Q26 Revenue between \$21.0M - \$22.6M

FY26 Revenue growth between 3% - 5%
(Raised from 2% - 4%)

ADJ. GROSS MARGIN*

3Q26 GM between 56% - 58%

FY26 GM between 57% - 59%
(Updated from 58% - 60%)

ADJ. EBITDA*

3Q26 Adj. EBITDA between \$1.5M - \$2.5M

FY26 Adj. EBITDA growth between 6% - 10%
(Maintained at 6% - 10%)

* Non-GAAP measure, see Slides 28-31 for reconciliation to GAAP financial measures

Investment Highlights: Strong Foundation Poised for Growth

Market Leadership with Structural Tailwinds	#1 preclinical telemetry franchise for 35+ years, & early organoid leadership
Blue-Chip Customer Base	Selling to diverse, blue-chip customer base on a global scale
Recurring Revenue, High Margins & Positive Cash Flow	Software, consumables, installed base drive visibility & margin expansion on products with high barrier to entry, generating increased cash for the Company
Differentiated New Product Innovation (NPI) Pipeline	MeshMEA™, SoHo™, Incub8™ extend leadership into high-growth adjacencies
New Management & BoD	Refocused management team with deep experience supported by technically deep employee base & refreshed board of directors
Strengthened Balance Sheet & Streamlined Operations	Refinancing & manufacturing consolidation unlock operating leverage

Appendix

Leading Reputation, with Multiple Competitive Advantages

A differentiated platform with durable market leadership

Breadth Across the Translational Workflow

- Only provider spanning in vivo telemetry & in vitro organoid platforms
- Enables standardized data & cross-selling across development stages

First-Mover & Technology Leadership

- Category-defining MeshMEA™ & decades of electrophysiology expertise
- Continuous innovation extending leadership into high-growth markets

Sticky Installed Base & Recurring Revenue

- Mission-critical software embedded in regulated customer workflows
- High switching costs with growing consumables & service revenue

Robust Data & Brand Equity

- Proprietary platforms validated in CRO & pharma environments
- Long-standing relationships & strong scientific reputation




Creates durable market leadership, strong pricing power, & long-term revenue visibility

2Q26 Revenue Breakdown



HBIO Revenue	2Q26	2Q25	% Var	
Americas	\$11.4M	\$10.1M	13%	Americas increase due to growth in CRO's telemetry business
EMEA	\$6.8M	\$6.6M	3%	EMEA growth due to CRO, pharma & distributors. EMEA up 1.5% on a constant currency basis
APAC	\$4.6M	\$3.7M	24%	APAC increase primarily driven by growth in BTX electroporation and respiratory
China	\$3.1M	\$2.4M	29%	
HBIO Total	\$22.7M	\$20.5M	11%	HBIO Total up 10% on a constant currency basis

Diversified Platform Powering the Full Translational Workflow

Two complementary engines covering critical stages of drug discovery through preclinical development while driving cash flow today & growth tomorrow



Pre-Clinical Systems Products



Cellular & Molecular Technology (CMT) Products



Non-GAAP Reconciliation Tables

Non-GAAP Reconciliation Table – Gross Margin

Non-GAAP Gross Profit and Non-GAAP Gross Margin	Three Months Ended June 30,				Six Months Ended June 30,			
	2026		2025		2026		2025	
	Amount	Margin	Amount	Margin	Amount	Margin	Amount	Margin
(in thousands)								
Gross profit	\$ 12,630	55.6%	\$ 11,533	56.4%	\$ 24,874	57.2%	\$ 23,717	56.2%
Adjustments:								
Stock-based compensation expense - cost of sales	15	0.1%	31	0.2%	21	0.0%	61	0.1%
Depreciation and amortization - cost of sales	195	0.9%	138	0.7%	399	0.9%	284	0.7%
Other adjustments - cost of sales (1)	44	0.2%	-	0.0%	45	0.1%	-	0.0%
Non-GAAP gross profit	\$ 12,884	56.7%	\$ 11,702	57.2%	\$ 25,339	58.3%	\$ 24,062	57.0%

(1) Other adjustments - cost of sales for the three months ended June 30, 2026 includes \$44 thousand of Non-GAAP restructuring-related charges compared to \$1 thousand of Non-GAAP restructuring-related charges. Other adjustments - cost of sales for the six months ended June 30, 2026 includes \$45 thousand of Non-GAAP restructuring-related charges.

Non-GAAP Reconciliation Table – Adjusted Operating Income

	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
GAAP operating loss	\$ (978)	\$ (819)	\$ (2,152)	\$ (50,487)
Stock-based compensation	380	472	637	1,072
Acquired asset amortization	820	1,162	1,640	2,322
Goodwill impairment	-	-	-	47,951
Other operating expenses (1)	318	200	553	464
Other adjustments (2)	579	30	671	42
Adjusted operating income	\$ 1,119	\$ 1,045	\$ 1,349	\$ 1,364
Operating margin	(4.3%)	(4.0%)	(4.9%)	(119.6%)
Adjusted operating margin	4.9%	5.1%	3.1%	3.2%

(1) Other operating expenses for the three months ended June 30, 2026 includes \$318 thousand of restructuring-related charges compared to \$30 thousand of restructuring-related charges and \$170 thousand of employee retention tax credit fees for the three months ended June 30, 2025. Other operating expenses for the six months ended June 30, 2026 includes \$553 thousand of restructuring-related charges compared to \$123 thousand of restructuring-related charges and \$341 thousand related to ERTC Fees for the six months ended June 30, 2025.

(2) Other adjustments for the three months ended June 30, 2026 includes \$579 thousand of Non-GAAP restructuring-related charges compared to \$30 thousand of Non-GAAP restructuring-related charges for the three months ended June 30, 2025. Other adjustments expenses for the six months ended June 30, 2026 includes \$671 thousand of Non-GAAP restructuring-related charges compared to \$42 thousand of Non-GAAP restructuring-related charges for the six months ended June 30, 2025.

Non-GAAP Reconciliation Table – Adjusted EBITDA

	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
GAAP net loss	\$ (2,910)	\$ (2,282)	\$ (6,334)	\$ (52,622)
Stock-based compensation	380	472	637	1,072
Acquired asset amortization	820	1,162	1,640	2,322
Goodwill impairment	-	-	-	47,951
Other operating expenses (1)	318	200	553	464
Other adjustments (2)	579	30	671	42
Income taxes	190	183	716	(16)
Adjusted net loss	(623)	(235)	(2,117)	(787)
Depreciation & amortization	549	456	1,086	950
Interest and other expense, net (2) (3)	1,918	1,435	4,051	2,561
Adjusted income taxes (4)	(177)	(156)	(585)	(410)
Adjusted EBITDA	\$ 1,667	\$ 1,500	\$ 2,435	\$ 2,314
Adjusted EBITDA margin	7.3%	7.3%	5.6%	5.5%

(1) Other operating expenses for the three months ended June 30, 2026 includes \$318 thousand of restructuring-related charges compared to \$30 thousand of restructuring-related charges and \$170 thousand of employee retention tax credit fees for the three months ended June 30, 2025. Other operating expenses for the six months ended June 30, 2026 includes \$553 thousand of restructuring-related charges compared to \$123 thousand of restructuring-related charges and \$341 thousand related to ERTC Fees for the six months ended June 30, 2025.

(2) Other adjustments for the three months ended June 30, 2026 includes \$579 thousand of Non-GAAP restructuring-related charges compared to \$30 thousand of Non-GAAP restructuring-related charges for the three months ended June 30, 2025. Other adjustments expenses for the six months ended June 30, 2026 includes \$671 thousand of Non-GAAP restructuring-related charges compared to \$42 thousand of Non-GAAP restructuring-related charges for the six months ended June 30, 2025.

(3) Interest expense for the three months ended June 30, 2026 was \$1.8 million, compared to \$1.0 million for the three months ended June 30, 2025. Interest expense for the six months ended June 30, 2026 was \$3.5 million, compared to \$1.9 million for the six months ended June 30, 2025.

(4) Adjusted income taxes includes the tax effect of adjusting for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise.

Non-GAAP Reconciliation Tables – Adjusted EPS & Net Debt

	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Diluted loss per share (GAAP) *	\$ (0.64)	\$ (0.52)	\$ (1.41)	\$ (11.91)
Diluted adjusted loss per share *	\$ (0.14)	\$ (0.05)	\$ (0.47)	\$ (0.18)
Weighted-average common shares:				
Diluted GAAP *	4,526	4,430	4,484	4,420
Diluted Adjusted *	4,526	4,430	4,484	4,420

	June 30,	
	2026	2025
Debt, including unamortized deferred financing costs	\$ 36,682	\$ 34,864
Unamortized deferred financing costs	3,318	486
Cash and cash equivalents	(6,503)	(7,442)
Net debt	\$ 33,497	\$ 27,908

* Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13, 2026.

